PRAME and neoplasm: For instance, the targeting of CTAs such as NY-ESO-1 and PRAME has shown notable pre-clinical anti-tumor activity and is currently undergoing evaluation in clinical trials using vaccine-based or adoptive cell therapy [6,7,8].